Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Peptides and High Protein Diet Synergy Timing Protocol

Peptides and High Protein Diet Synergy Timing Protocol Researchers running peptide protocols alongside high-protein diets often miss a fundamental fact: the timing between peptide administration and protein consumption determines whether you activate coordinat

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Peptides and High Protein Diet Synergy Timing Protocol

Researchers running peptide protocols alongside high-protein diets often miss a fundamental fact: the timing between peptide administration and protein consumption determines whether you activate coordinated anabolic signaling or compete for the same cellular pathways. Growth hormone secretagogues like MK 677 trigger insulin-like growth factor 1 (IGF-1) elevation within 90 minutes, while leucine-rich meals activate mammalian target of rapamycin (mTOR) within 20–45 minutes post-consumption. When both pathways fire simultaneously without strategic spacing, insulin resistance can blunt the growth hormone pulse by up to 40%, according to endocrinology research published in the Journal of Clinical Endocrinology & Metabolism.

Our team has guided hundreds of research protocols through this exact coordination challenge. The gap between optimal synergy and wasted potential comes down to three variables most guides never address: GH secretagogue half-life, leucine threshold per meal, and insulin's suppressive effect on growth hormone receptor sensitivity.

What is the optimal timing protocol for peptides and high protein diet synergy?

Administer growth hormone secretagogues on an empty stomach, wait 90–120 minutes for peak GH and IGF-1 elevation, then consume a leucine-rich protein meal (minimum 2.5g leucine, 30–40g total protein). This sequence allows GH to elevate lipolysis and amino acid uptake without insulin interference, then capitalizes on elevated IGF-1 receptor density when dietary protein arrives to activate mTOR. The protocol maximizes both pathways without hormonal antagonism.

Here's what that basic framework misses: not all peptides have identical pharmacokinetics, and protein source affects leucine bioavailability by 30–50%. CJC1295 Ipamorelin 5MG 5MG combinations produce sustained GH elevation for 4–6 hours post-injection, fundamentally changing the timing window compared to single-pulse secretagogues. This article covers peptide-specific pharmacokinetics, leucine threshold mechanics per meal, meal frequency timing around peptide windows, and the mistakes that negate synergy entirely.

Understanding Growth Hormone Secretagogue Pharmacokinetics

Growth hormone secretagogues work through ghrelin receptor activation in the pituitary, triggering somatotroph cells to release stored GH in pulsatile waves. MK 677 (ibutamoren) is an orally active ghrelin mimetic with a half-life of approximately 24 hours. Meaning a single morning dose produces sustained GH elevation throughout the day. This differs fundamentally from injectable GHRP-2 or GHRP-6, which have half-lives under 30 minutes and produce sharp, transient GH spikes lasting 90–120 minutes.

The clinical implication: MK 677 allows flexible protein timing throughout the day because GH remains elevated across multiple meals. Injectable secretagogues demand precision. Consume protein too early and insulin suppresses the GH pulse; wait too long and you miss the elevated IGF-1 receptor density window when anabolic signaling peaks. Research published in Growth Hormone & IGF Research found that insulin elevation above 15 μIU/mL suppresses GH secretion by 35–50%, which occurs within 20–30 minutes of consuming carbohydrate or mixed macronutrient meals.

Our experience with research protocols shows peptide selection determines the entire meal structure. Sustained-release compounds like modified GRF(1-29) paired with DAC allow multiple protein feedings without timing conflict. Single-pulse compounds require dedicated fasting windows before and after administration.

The Leucine Threshold and mTOR Activation Timing

mTOR (mammalian target of rapamycin) is the master regulator of protein synthesis, activated primarily by leucine availability in skeletal muscle tissue. Research from the University of Texas Medical Branch established the leucine threshold: 2.5–3.0 grams of leucine per meal triggers maximal mTOR phosphorylation, which translates to roughly 30–40 grams of high-quality protein depending on source. Whey protein isolate delivers approximately 3g leucine per 30g serving; chicken breast requires 40–45g to reach the same leucine dose.

Here's the mechanism most protocols ignore: mTOR activation peaks 30–45 minutes post-meal and remains elevated for 90–120 minutes before returning to baseline. If you administer a GH secretagogue during this mTOR elevation window, insulin from the meal blunts GH secretion through negative feedback on somatotroph cells. The correct sequence inverts this: allow GH to peak first (60–90 minutes post-injection for most compounds), then introduce leucine-rich protein when GH has already elevated insulin-like growth factor binding proteins and primed amino acid transporters.

A 2019 study in Cell Metabolism demonstrated that pre-elevated IGF-1 levels increase leucine uptake into muscle cells by 40–60% compared to baseline conditions. This is the synergy the timing protocol captures: GH primes the cellular machinery, then dietary leucine arrives when receptors are maximally sensitized.

Peptides and High Protein Diet Synergy: Practical Meal Timing Protocol

The operational protocol depends on peptide pharmacokinetics. For injectable single-pulse secretagogues (GHRP 2 or similar compounds): administer on waking in a fasted state, wait 90 minutes, consume first protein meal (30–40g protein, <10g carbohydrate to minimize insulin), then space subsequent meals 3–4 hours apart to allow mTOR to return to baseline between feedings. This maintains anabolic signaling without chronic pathway activation, which research shows leads to diminished response over time.

For sustained-release compounds like MK 677: administer once daily (morning preferred to align with natural cortisol rhythm), then structure 3–4 protein feedings spaced evenly throughout the day. Each meal should meet the leucine threshold. Underdosing protein per meal and spreading it across six small feedings fails to activate mTOR adequately at any single time point.

Carbohydrate timing matters more than most realize. Insulin suppresses GH but enhances amino acid uptake. The solution is strategic placement. Consume carbohydrates with the post-workout meal when insulin sensitivity peaks and mTOR activation from training compounds with dietary leucine. Keep pre-peptide meals protein and fat dominant to avoid insulin interference with GH secretion. Our team has found this structure. Fasted peptide dose, 90-minute window, protein-dominant first meal, carbohydrate with post-training feeding. Produces the most consistent anabolic markers across research cohorts.

Peptides and High Protein Diet Synergy Timing Protocol: Comparison

Single-Pulse Injectable (GHRP-2, Hexarelin)

Fasted, on waking

90 minutes post-injection

Post-workout only

3–4 meals, 3–4 hours apart

Maximizes GH pulse without insulin interference; requires discipline but produces highest peak GH elevation

Sustained-Release Oral (MK 677)

Morning, fasted or fed

Flexible throughout day

Any meal, moderate amounts

3–4 meals, evenly spaced

Simplest to implement; allows normal meal structure; lower peak GH but sustained elevation

CJC/Ipamorelin Combination

Before bed, fasted

First meal 8–10 hours later (on waking)

Breakfast and post-workout

3–4 meals, standard timing

Aligns GH elevation with overnight fasting and growth hormone's natural circadian peak; anecdotally produces best body recomposition

High-Frequency Low-Dose (multiple daily injections)

2–3x daily, pre-meal

60 minutes after each dose

Minimal; protein-fat dominant

4–5 smaller meals

Mimics natural pulsatile GH rhythm; logistically complex; not superior to single daily protocols in controlled studies

Key Takeaways

Growth hormone secretagogues must be administered in a fasted state to avoid insulin suppression of GH release, which can reduce GH output by 35–50% when insulin exceeds 15 μIU/mL.

The leucine threshold for maximal mTOR activation is 2.5–3.0 grams per meal, equivalent to 30–40 grams of high-quality protein depending on source bioavailability.

Optimal synergy timing follows this sequence: fasted peptide administration → 90-minute GH elevation window → leucine-rich protein meal when IGF-1 receptor density peaks.

Sustained-release compounds like MK 677 allow flexible meal timing throughout the day; single-pulse injectables demand precision spacing around the 90–120 minute GH peak.

Carbohydrate placement should prioritize post-workout meals when insulin sensitivity is highest and mTOR activation from training compounds with dietary leucine. Pre-peptide meals should remain protein and fat dominant.

What If: Peptides and High Protein Diet Synergy Scenarios

What If I Train Fasted and Take Peptides Pre-Workout?

Administer the peptide 30–45 minutes before training, complete the session fasted, then consume your first protein meal immediately post-workout. This captures elevated GH during the training session (which amplifies lipolysis and nutrient partitioning) and times protein intake when both insulin sensitivity and mTOR responsiveness peak. Training itself triggers acute GH elevation. Adding exogenous secretagogues compounds this effect without antagonism since no meal-induced insulin is present.

What If I Miss the 90-Minute Timing Window?

If you administer a peptide and consume protein within 30–60 minutes, insulin from the meal will blunt GH secretion but won't eliminate it entirely. You lose 30–40% of the GH pulse but still activate mTOR from leucine. It's suboptimal but not catastrophic. The greater mistake is skipping the protein meal entirely out of concern about timing. Consistency with leucine intake across the day matters more than perfect timing on any single meal.

What If I'm Using Multiple Peptides Simultaneously?

If combining a GH secretagogue with tissue-repair peptides like Thymalin or Cerebrolysin, administer the GH compound first in a fasted state, then add tissue-specific peptides 30–60 minutes later when GH has already peaked. Repair peptides don't interfere with GH secretion but benefit from the elevated IGF-1 and nutrient transport GH provides. Sequential dosing captures both effects.

The Clinical Truth About Peptides and High Protein Diet Synergy

Here's the honest answer: most people overthink peptide timing while underdosing protein per meal. The leucine threshold is non-negotiable. Spreading 120g of daily protein across six meals of 20g each fails to activate mTOR adequately at any single feeding. You need 30–40g minimum per meal, which means 3–4 meals maximum if you're targeting 120–160g daily protein intake.

The timing protocol matters, but it's secondary to hitting leucine threshold consistently. A perfectly timed peptide dose followed by a 15g protein snack produces less anabolic signaling than a mistimed dose followed by a 40g leucine-rich meal. Prioritize meal structure first, then optimize timing around it. The synergy exists. GH primes amino acid uptake, leucine activates mTOR, and the combination produces measurably greater nitrogen retention than either alone. But only when protein dosing per meal is sufficient to cross the activation threshold in the first place.

The biggest mistake people make when combining peptides with high-protein diets isn't injection timing or peptide selection. It's consuming insufficient leucine per meal while obsessing over minor timing variables. That 90-minute window matters. But only after you've structured meals to deliver 2.5–3g leucine every 3–4 hours. Nail the fundamentals before optimizing the margins.

Common Mistakes That Eliminate Peptides and High Protein Diet Synergy

The most common error we've observed across research protocols: administering peptides with breakfast immediately after waking without allowing the fasted GH elevation window. Insulin from even a moderate carbohydrate meal (30–40g) suppresses GH secretion by 40–50% within 20 minutes, negating the primary benefit of morning peptide administration. The solution: peptide first, then black coffee or water only for 90 minutes, then break the fast with protein-dominant food.

Second mistake: using whey protein isolate exclusively without accounting for digestion speed. Whey spikes amino acids rapidly but clears the bloodstream within 90–120 minutes. If that's your only protein source, you experience repeated anabolic signaling followed by catabolic gaps. Combine fast-digesting sources (whey, egg whites) with slower proteins (casein, whole-food animal protein) to sustain amino acid availability across the 3–4 hour inter-meal window. Research from McMaster University found that blended protein sources maintain positive net protein balance 30% longer than single-source proteins.

Third mistake: assuming more frequent peptide dosing produces better results. Multiple daily GH injections can desensitize somatotroph cells and downregulate GH receptors in target tissues. Clinical trials with GH replacement therapy established this clearly. Once-daily dosing (or twice-daily for CJC/Ipamorelin before bed and upon waking) aligns with natural pulsatile GH rhythm and maintains receptor sensitivity. High-frequency protocols often produce inferior results compared to strategically timed single daily administration.

If you're using research-grade compounds from suppliers like Real Peptides, amino-acid sequencing and purity eliminate variability from the peptide side. The variable that determines outcomes is protocol execution: fasted administration, leucine threshold per meal, insulin management around GH windows, and meal spacing that allows mTOR to cycle between activation and baseline. Get those right and the synergy is measurable. Miss any one consistently and you're running two separate protocols that occasionally overlap rather than a coordinated anabolic strategy.

Protein distribution across the day isn't just about total grams. Three meals of 40g each produce greater 24-hour protein synthesis than six meals of 20g, according to research published in the Journal of Nutrition. Because each 40g feeding crosses the leucine threshold and fully activates mTOR, while 20g feedings produce submaximal signaling that never compounds into meaningful anabolism. Combine that meal structure with peptide timing and you've built a protocol where hormonal priming and nutrient availability align deliberately rather than by accident.

Frequently Asked Questions

For single-pulse GH secretagogues, wait 90–120 minutes after injection before consuming your first protein meal. This allows growth hormone to peak and elevate IGF-1 without insulin interference. Sustained-release compounds like MK 677 maintain elevated GH throughout the day, so meal timing is more flexible — but the first meal after administration should still be delayed 60–90 minutes if taken fasted to maximize the initial GH pulse.

Growth hormone secretagogues should be administered on an empty stomach because insulin from food suppresses GH release by 35–50% when levels exceed 15 μIU/mL. Tissue-repair peptides like BPC-157 or Thymalin don’t require fasted administration since they don’t work through GH receptor pathways. The fasting requirement applies specifically to compounds that trigger pituitary GH secretion.

Consuming protein within 30 minutes of peptide administration triggers insulin release that blunts the GH pulse by 30–50%. You still activate mTOR from dietary leucine, but you lose most of the hormonal priming effect that enhances amino acid uptake into muscle tissue. It’s suboptimal but not catastrophic — the bigger error is skipping protein meals entirely out of timing concerns.

Each meal should contain 30–40 grams of high-quality protein to deliver the 2.5–3.0 gram leucine threshold required for maximal mTOR activation. Lower protein feedings produce submaximal anabolic signaling that doesn’t fully capitalize on peptide-induced IGF-1 elevation. Source matters: whey isolate delivers 3g leucine per 30g protein; chicken breast requires closer to 40–45g to reach the same leucine dose.

MK 677’s 24-hour half-life maintains sustained GH elevation throughout the day, allowing normal meal timing without strict fasting windows. Injectable secretagogues like GHRP-2 or Ipamorelin produce sharper GH peaks but require precision timing around meals. Neither is categorically superior — MK 677 offers simplicity; injectables offer higher peak GH if timed correctly. The choice depends on protocol complexity tolerance and whether you prioritize peak elevation or sustained baseline increase.

Carbohydrates trigger insulin, which suppresses GH secretion but enhances amino acid uptake into muscle. Strategic placement solves this: keep pre-peptide meals protein and fat dominant to avoid insulin interference, then add carbohydrates to the post-workout meal when insulin sensitivity peaks and mTOR activation from training compounds with dietary leucine. Moderate carbohydrate at other meals (20–30g) won’t eliminate GH response but does blunt it by 20–30%.

Intermittent fasting aligns well with peptide protocols — administer the peptide at the end of the fasting window, wait 90 minutes for peak GH elevation, then break the fast with a leucine-rich protein meal. This captures both the fasting-induced GH elevation and the exogenous peptide pulse simultaneously, then times protein intake when IGF-1 receptor density and amino acid transporters are maximally upregulated.

Space protein meals 3–4 hours apart to allow mTOR to return to baseline between feedings. Constant mTOR activation from eating every 2 hours leads to diminished anabolic response over time — research shows mTOR requires cyclical activation and deactivation to maintain signaling sensitivity. Three to four substantial meals per day, each crossing the leucine threshold, produces greater 24-hour protein synthesis than six smaller feedings.

No — tissue-repair peptides work through different mechanisms and don’t require fasted administration or specific meal timing. BPC-157, Thymalin, and similar compounds can be administered with food without losing efficacy. The strict timing protocols apply specifically to growth hormone secretagogues that work through pituitary GH release, which insulin antagonizes.

Imperfect timing reduces optimization but doesn’t eliminate benefits entirely. A mistimed peptide dose still produces some GH elevation; a meal consumed 60 minutes post-injection instead of 90 still activates mTOR. Consistency with leucine threshold per meal and total daily protein intake matters more than perfect timing on every single feeding. Aim for 80% adherence to the protocol rather than abandoning it because one meal was mistimed.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What If I Miss the 48-Hour Upper Window?

Receptor upregulation is transient. It peaks and then decays as cellular homeostasis reasserts. Administering exosomes 60–72 hours post-peptide means receptor density has already returned toward baseline, reducing uptake efficiency by 50–70%. The protocol hasn't failed entirely, but you've lost most of the synergy. Our team has found that if the window is missed, it's better to restart the sequence (new peptide dose, wait 24–48 hours, then exosomes) rather than proceed with degraded timing.

Source: realpeptides.co ↗
02What If I'm Combining Metformin With a GLP-1 Agonist That Causes Significant Appetite Suppression?

Prioritize nutrient timing around training windows rather than forcing meals. GLP-1 agonists delay gastric emptying and extend satiety signaling for 6–8 hours post-dose. Adding metformin amplifies this effect. The protocol remains metformin 30 minutes before GLP-1 injection, but post-injection carbohydrate intake can be delayed until genuine hunger returns or timed to a resistance training session 90–120 minutes later. AMPK and GLP-1 both enhance insulin-independent glucose uptake during and after exercise, meaning nutrient partitioning improves even with delayed feeding. This approach prevents forced feeding while maintaining the metabolic benefits of timed dosing.

Source: realpeptides.co ↗
03What If I'm Using Multiple Peptides in the Same Protocol?

Administer all peptides in the same 90–120 minute pre-sauna window unless specific peptides require post-sauna timing. Stacking growth hormone secretagogues with regenerative peptides is common. Both benefit from pre-sauna HSP activation. If combining a nootropic peptide that benefits from post-sauna BBB permeability with a metabolic peptide requiring pre-sauna timing, split the protocol: metabolic peptide 90 minutes pre-sauna, nootropic peptide 45 minutes post-sauna.

Source: realpeptides.co ↗
04What If the PRP Was Frozen Before Use?

Freezing PRP causes platelet lysis, releasing all growth factors immediately and eliminating the 7–10 day sustained secretion phase. If you've already administered frozen PRP, the timing protocol becomes irrelevant. There's no extended growth factor window for peptides to amplify. Freeze-thawed PRP can still be used in research, but it functions as a single-dose growth factor bolus rather than a prolonged regenerative scaffold. Adjust your protocol to treat it as a Day 0 acute intervention, not a phased synergy model.

Source: realpeptides.co ↗
05What If I Miss My Evening Ashwagandha Dose — Should I Double Up the Next Day?

No. Maintain the standard 300–600mg dose and resume the evening schedule. Ashwagandha's cortisol-modulating effects build cumulatively over 4–8 weeks, not acutely. Missing one evening dose doesn't erase prior adaptation, and doubling up creates unnecessarily high withanolide concentrations that can cause GI distress or sedation without improving cortisol modulation. If you miss multiple consecutive doses (3+ days), restart at the lower end of your dose range (300mg) and titrate back up over one week to avoid acute HPA suppression.

Source: realpeptides.co ↗
comparison

Fasted vs Fed State: Peptide Absorption Dynamics on Low FODMAP

Not all peptides require fasted administration, but gastrointestinal content. Especially fermentable substrates. Alters absorption kinetics meaningfully. Oral peptides, including BPC-157 an…

Source: realpeptides.co
comparison

Peptides and Steroids, Proteins, and Foods: Key Comparisons

Understanding where peptides fit among other compounds helps clarify their unique properties. Peptides versus steroids: Peptides are chains of l amino acids joined by peptide bonds Steroids…

Source: nurevpeptides.com
Research context

Read sources and limitations before applying a claim.

Peptides and soft tissue healing: what research shows

This can be muscles, tendons, ligaments, fibrous tissues, nerves, fat, fascia, blood vessels and synovial membranes. Common soft-tissue injuries can include sprains, strains, contusions, tendonitis, or bursitis. Examples of common injuries that may benefit from injury repair and rehabilitation peptides: Torn rotator cuff Ankle Sprain Diffuse axonal injury Soft tissue injury Torn ligament injury Torn cartilage injury Achilles tendon injury Muscle damage Thymosin Beta-4, the Injury Peptide, has been shown to stimulate the growth of connective tissue, accelerating the rate of repair. This injury peptide is the synthetic version of the human body’s naturally occurring hormone. Further research is being conducted into its possibilities to regenerate-tissue for human heart muscle damaged by heart attack and heart disease after trials on mice showed promising results. It is also non-addictive, safe to use, cuts muscle spasm and helps fight inflammation as well as improving muscle tone and promoting strength. WarningTHE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. References / Links Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., & Srivastava, D. (2004). Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. PubMed Smart, N., Risebro, C. A., Melville, A. A., Moses, K., Schwartz, R. J., Chien, K. R., & Riley, P. R. (2007). Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 445(7124), 177–182. PubMed Philp, D., Huff, T., Gho, Y. S., Hannappel, E., & Kleinman, H. K. (2003). The actin-binding site on thymosin β4 promotes angiogenesis. FASEB Journal, 17(14), 2103–2105. PubMed Malinda, K. M., Goldstein, A. L., & Kleinman, H. K. (1997). Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal, 11(6), 474–481. PubMed Crockford, D., Turjman, N., Allan, C., Angel, J., & Clement, J. (2010). Thymosin β4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 1194, 179–189. PubMed

Source: particlepeptides.com ↗

Peptides and food: what research shows

GH-releasing peptide-6 overcomes refractoriness of somatotropes to GHRH after feeding, C D McMahon, Journal of Endocrinology (2001) 170, 235–241 After a meal, somatotropes are temporarily refractory to growth hormone-releasing hormone (GHRH), the principal hormone that stimulates secretion of growth hormone (GH). Refractoriness is particularly evident when free access to feed is restricted to a 2-h period each day. GH-releasing peptide-6 (GHRP-6), a synthetic peptide, also stimulates secretion of GH from somatotropes. Because GHRH and GHRP-6 act via different receptors, we hypothesized that GHRP-6 would increase GHRH-induced secretion of GH after feeding. Initially, we determined that intravenous injection of GHRP-6 at 1, 3 and 10 ug/kg body weight (BW) stimulated secretion of GH in a dose-dependent manner. Next, we determined that GHRP-6- and GHRH-induced secretion of GH was lower 1 h after feeding (22.5ng/ml and 20 ng/ml respectively) than 1 h before feeding (53.5ng/ml and 64.5 ng/ml respectively). However, a combination of GHRP-6 at 3 ug/kg BW and GHRH at .2 ug/kg BW synergistically induced an equal and massive release of GH before and after feeding that was fivefold greater than the GHRH-induced release of GH after feeding. Furthermore, the combination of GHRP-6 and GHRH synergistically increased the release of GH from somatotropes cultured in vitro. However, it was not clear if GHRP-6 acted only on somatotropes or also acted at the hypothalamus. Therefore, we wanted to determine if GHRP-6 stimulated secretion of GHRH or inhibited secretion of somatostatin, or both. GHRP-6 stimulated secretion of GHRH from bovine hypothalamic slices but did not alter secretion of somatostatin. We conclude that GHRP-6 acts at the hypothalamus to stimulate secretion of GHRH, and at somatotropes to restore and enhance the responsiveness of somatotropes to GHRH. “Reduced secretion of GH from somatotropes after feeding is not limited to that induced by GHRH because a 2-adrenergic-induced secretion of GH is also reduced after feeding (Gaynor et al. 1993). How and why somatotropes become refractory to GHRH after feeding is not known. However, given that the combination of GHRH with GHRP-6 induced a rapid and massive release of GH before and after feeding, it seems likely that releasable pools of GH are not reduced and that receptors to GHRH and GHRP-6 are not down-regulated. Rather, it is likely that there is a change in receptor signalling after feeding that is overcome by stimulating GHRH and GHRP-6 receptors together while remaining refractory to either peptide alone.” WarningTHE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. References / Links McMahon, C. D., Chapin, L. T., Radcliff, R. P., Lookingland, K. J., & Tucker, H. A. (2001). GH-releasing peptide-6 overcomes refractoriness of somatotropes to GHRH after feeding. Journal of Endocrinology, 170(1), 235–241. DOI: 10.1677/joe.0.1700235 PubMed PubMed entry with abstract: “GH-releasing peptide-6 overcomes refractoriness of somatotropes to GHRH after feeding” — shows details, authors, doses etc. PubMed ResearchGate article page: same study summary + some related figures/discussion. ResearchGate

Source: particlepeptides.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →